ArticleJournal of mood and anxiety disorders2026
The prevalence and burden of generalized anxiety disorder in the United States healthcare system: Real-world prevalence and incidence from 2020 to 2023.
Article in Journal of mood and anxiety disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Changes in Anxiety Severity and Acceptability of Venlafaxine in Generalized Anxiety Disorder in the United States: Results From a Real-World Study.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Generalized anxiety disorder (GAD) is characterized by persistent, difficult-to-control worry that is often accompanied by substantial comorbidity, impairment, and reduced quality of life. Yet, its prevalence in the United States remains uncertain and may be underestimated. Methods: We estimated the prevalence and incidence of diagnosed GAD among adults in the U.S. healthcare system using payer-complete closed claims data from the Komodo Healthcare Map™ database from January 1, 2020 to December 31, 2023. Patients with GAD were identified using ICD-10 code F41.1. Annual and three-year prevalence, as well as annual incidence rates, were calculated and projected to the U.S. adult population. Results: From 2021-2023, most patients diagnosed with GAD were women, middle-aged, and commercially insured with women diagnosed at more than twice the rate of men. Projected annual prevalence increased from 5.4% in 2020-6.6% in 2023, with a 3-year prevalence of 10.3% over the 2021-2023 period. The projected annual incidence ranged from 2.1% to 2.3%. Conclusion: The increasing prevalence of GAD diagnoses may reflect multiple converging factors, including increased screening and recognition. Together, these updated national estimates highlight not only the increasing prevalence of GAD but also the need to expand access to care and improve the effectiveness of treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.